Form 4: Voyager Therapeutics CEO Alfred Sandrock Sells Shares to Cover Tax Obligations

Voyager Therapeutics CEO Alfred Sandrock sold 16,644 shares of common stock on February 11, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Alfred Sandrock, the President and CEO of Voyager Therapeutics, sold 16,644 shares of common stock on February 11, 2025.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units on February 9, 2025.
• The shares were sold at a weighted average price of $4.45, with individual transactions ranging from $4.13 to $5.00.
• Following the transaction, Sandrock beneficially owns 308,518 shares of Voyager Therapeutics.
• This total includes 2,323 shares acquired under the company's Employee Stock Purchase Plan since his last Form 4 filing.

Sentiment

Score: 6

Explanation: The document describes a routine transaction (stock sale for tax obligations) by the CEO. It's neutral to slightly positive as it indicates the CEO is receiving vested stock units, suggesting continued employment and vesting schedules.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future.

Comparison to Industry Standards

• Executive stock sales for tax purposes are a routine occurrence across publicly traded companies.
• Similar transactions are frequently observed among executives at comparable biotech firms like Biogen, Vertex Pharmaceuticals, and CRISPR Therapeutics.
• These sales are typically disclosed via Form 4 filings with the SEC, providing transparency to investors.

Stakeholder Impact

• The stock sale may have a minor, temporary impact on the stock price due to the increased supply of shares.
• However, since the sale is for tax purposes, it's unlikely to significantly alter investor sentiment.

Key Dates